This founder has spent a decade building a multi-million-dollar spice company that is almost profitable. She still doesn’t want your venture capital dollars—at least not for now

Platinum prices shot up impressively in June, but experts are now warning that the rally might be running out of steam. While the surge was welcome news for miners and investors, market analysts suggest there’s little room left for further gains in the near term due to mixed demand signals and economic uncertainties.

Editor’s Note: If you’re keeping an eye on precious metals, this is a heads-up—platinum’s hot streak may be cooling off. The metal’s recent jump was driven by a mix of supply concerns and speculative trading, but shaky industrial demand (especially from the auto sector, which uses platinum in catalytic converters) and broader economic jitters could cap further price hikes. For investors, it’s a reminder that not every rally lasts forever.

Gold Reserve, a Canadian mining company, has been recommended as the winning bidder in the high-stakes auction for Citgo Petroleum, with a whopping $7.38 billion offer. If finalized, this could mark the end of a years-long legal and financial saga surrounding Citgo, Venezuela’s prized foreign asset, which has been caught in geopolitical crossfires.

Editor’s Note: This isn’t just another corporate deal—it’s a major turning point in a messy, years-long battle over Citgo, which was essentially Venezuela’s crown jewel abroad. The auction stems from legal battles tied to Venezuela’s unpaid debts and sanctions. If Gold Reserve’s bid goes through, it could reshape the energy landscape and finally bring some resolution to a tangled international dispute. For everyday folks, it’s a reminder of how global politics and big money collide in the oil industry.

Oil prices dipped as traders weighed concerns over potential US tariffs on Chinese goods and rumors that OPEC+ might ramp up production soon. The combination of trade tensions and possible oversupply spooked the market, pulling prices down from recent highs.

Editor’s Note: If you’ve been watching gas prices lately, this could signal some relief at the pump—but don’t celebrate just yet. Trade wars and OPEC+ decisions are wild cards, and any shifts could swing prices right back up. For drivers and businesses, it’s another reminder of how global politics and oil giants keep energy costs on a rollercoaster.

Summit Therapeutics and AstraZeneca are reportedly in discussions about a massive $15 billion deal that would give AstraZeneca the rights to license Summit's experimental cancer drug. If it goes through, this could be a game-changer for both companies—Summit would get a major financial boost and validation for its research, while AstraZeneca could add a promising new therapy to its already strong oncology portfolio.

Editor’s Note: Big pharma deals like this don’t happen every day, and a $15 billion price tag signals serious confidence in the drug’s potential. For patients, it could mean faster access to a new treatment if the drug succeeds in trials. For the industry, it’s another sign that cancer research remains a high-stakes, high-reward space—especially when giants like AstraZeneca are willing to bet billions.

Former President Trump is set to have separate calls with Russian President Putin and Ukrainian President Zelensky, just as the U.S. puts a hold on weapons shipments to Ukraine. The timing raises eyebrows, given Trump's past pro-Russia leanings and the ongoing war.

Editor’s Note: This isn't just routine diplomacy—it's a high-stakes moment. With Ukraine desperate for U.S. weapons to fend off Russian advances, freezing aid now could weaken their position. Trump's simultaneous outreach to both leaders adds fuel to concerns about whose interests he might prioritize. For Ukraine, this could signal trouble ahead.